- Home
- MGTX vs SAGE Comparison
MGTX vs SAGE Comparison
Compare MGTX & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- SAGE
- Stock Information
- Founded
- MGTX 2015
- SAGE 2010
- Country
- MGTX United States
- SAGE United States
- Employees
- MGTX N/A
- SAGE N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- MGTX Health Care
- SAGE Health Care
- Exchange
- MGTX Nasdaq
- SAGE Nasdaq
- Market Cap
- MGTX 520.8M
- SAGE 571.1M
- IPO Year
- MGTX N/A
- SAGE 2014
- Fundamental
- Price
- MGTX $8.47
- SAGE $9.27
- Analyst Decision
- MGTX Strong Buy
- SAGE Hold
- Analyst Count
- MGTX 2
- SAGE 18
- Target Price
- MGTX $24.00
- SAGE $9.89
- AVG Volume (30 Days)
- MGTX 541.8K
- SAGE 3.2M
- Earning Date
- MGTX 08-11-2025
- SAGE 07-30-2025
- Dividend Yield
- MGTX N/A
- SAGE N/A
- EPS Growth
- MGTX N/A
- SAGE N/A
- EPS
- MGTX N/A
- SAGE N/A
- Revenue
- MGTX $34,508,000.00
- SAGE $47,404,000.00
- Revenue This Year
- MGTX $365.04
- SAGE $102.21
- Revenue Next Year
- MGTX $73.18
- SAGE $43.01
- P/E Ratio
- MGTX N/A
- SAGE N/A
- Revenue Growth
- MGTX 203.23
- SAGE N/A
- 52 Week Low
- MGTX $3.85
- SAGE $4.62
- 52 Week High
- MGTX $8.75
- SAGE $13.47
- Technical
- Relative Strength Index (RSI)
- MGTX 76.43
- SAGE 73.46
- Support Level
- MGTX $6.31
- SAGE $9.10
- Resistance Level
- MGTX $8.75
- SAGE $9.22
- Average True Range (ATR)
- MGTX 0.45
- SAGE 0.12
- MACD
- MGTX 0.19
- SAGE -0.05
- Stochastic Oscillator
- MGTX 89.55
- SAGE 71.88
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.